Blar i forfatter Det helsevitenskapelige fakultet "Yamazaki, Takahiro"

Viser treff 1-3 av 3

    • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death 

      Galluzzi, Lorenzo; Vitale, Ilio; Warren, Sarah; Adjemian, Sandy; Agostinis, Patrizia; Martinez, Aitziber Burque; Chan, Timothy A.; Coukos, George; Demaria, Sandra; Deutsch, Eric; Draganov, Dobrin; Edelson, Richard L; Formenti, Silvia C.; Fucikova, Jitka; Gabriele, Lucia; Gaipl, Udo S.; Gameiro, Sofia R.; Garg, Abhishek D.; Golden, Encouse; Han, Jian; Harrington, Kevin J.; Hemminki, Akseli; Hodge, James W.; Hossain, Dewan Md Sakib; Illidge, Tim; Karin, Michael; Kaufman, Howard L.; Kepp, Oliver; Kroemer, Guido; Lasarte, Juan Jose; Loi, Sherene; Lotze, Michael T.; Manic, Gwenola; Merghoub, Taha; Melcher, Alan A.; Mossman, Karen L.; Prosper, Felipe; Rekdal, Øystein; Rescigno, Maria; Riganti, Chiara; Sistigu, Antonella; Smyth, Mark J.; Spisek, Radek; Stagg, John; Strauss, Bryan E.; Tang, Daolin; Tatsuno, Kazuki; van Gool, Stefaan W.; Vandenabeele, Peter; Yamazaki, Takahiro; Zamarin, Dmitriy; Zitvogel, Laurence; Cesano, Alessandra; Marincola, Francesco M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-09)
      Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death ...

    • LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells 

      Yamazaki, Takahiro; Wennerberg, Erik; Hensler, Michal; Buqué, Aitziber; Kraynak, Jeffrey; Fucikova, Jitka; Zhou, Xi Kathy; Rekdal, Øystein; Demaria, Sandra; Galluzzi, Lorenzo (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-08-10)
      LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to promote tumortargeting immune responses. Here, we investigated the therapeutic activity and immunological ...

    • Tumor lysis with LTX-401 creates anticancer immunity 

      Xie, Wei; Mondragon, Laura; Mauseth, Brynjar; Wang, Yan; Pol, Jonathan; Levesque, Sarah; Zhou, Heng; Yamazaki, Takahiro; Eksteen, Jacobus Johannes; Zitvogel, Laurence; Sveinbjørnsson, Baldur; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-13)
      Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and ...